Chiesi Archives -

News/ News/ Press Releases/ R&D/ Views and analysis

Touring Chiesi’s vision for the future at the new Biotech Centre of Excellence

Nicole Raleigh Alberto Chiesi, Antonio Magnelli, biologics, Biotech, Biotech Centre of Excellence, Chiesi, Chiesi Group, Francesca Usberti, Italy, Marcello Catani, Michele Guerra, monoclonal antibodies, Parma, pharma, R&D, Rare diseases, Stefano Bonaccini, Valentino Valentini, Vincenzo Colla 0 Comment

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure

Touring Chiesi’s vision for the future at the new Biotech Centre of Excellence

https://pharmaphorum.com/views-and-analysis/touring-chiesis-vision-for-the-future-at-the-new-biotech-centre-of-excellence/

Digital/ News/ News/ News/ Patients

Chiesi joins with Aptar on digital platform for respiratory patients

Phil Taylor Aptar, asthma, Chiesi, Chronic Obstructive Pulmonary Disease, digital, digital health, disease management, respiratory 0 Comment

Hard on the heels of the official launch of its digital disease management platform, Aptar Pharma has secured

Chiesi joins with Aptar on digital platform for respiratory patients

https://pharmaphorum.com/news/chiesi-joins-with-aptar-on-digital-platform-for-respiratory-patients/

Market Access/ News/ News/ News/ Patients

FDA starts review of first drug for alpha-mannosidosis, from Chiesi

Phil Taylor alpha-mannosidosis, Chiesi, enzyme replacement therapy, Lamzede, rare disease 0 Comment

The FDA has started a priority review of Chiesi ‘s velmanase alfa, an enzyme replacement therapy for lysosomal

FDA starts review of first drug for alpha-mannosidosis, from Chiesi

https://pharmaphorum.com/news/fda-starts-review-of-first-drug-for-alpha-mannosidosis-from-chiesi/

News/ News/ Patients

Rare diseases have tenfold higher impact on healthcare costs; study

Phil Taylor Chiesi, IQVIA, Rare Disease Day, Rare diseases 0 Comment

A new study has suggested that the economic burden posed by rare diseases is around 10 times higher

Rare diseases have tenfold higher impact on healthcare costs; study

https://pharmaphorum.com/news/rare-diseases-have-tenfold-higher-impact-on-healthcare-costs-study/

Sales and Marketing/ Views & Analysis/ Views and analysis

The benefits of being a family-run pharma company

mike.hammerton@pharmaphorum.com Chiesi, Rare diseases 0 Comment

The third generation of his family to hold a leadership role at Chiesi Group, Giacomo Chiesi reflects on

The benefits of being a family-run pharma company

https://pharmaphorum.com/sales-marketing/chiesi-family-run-pharma-company-benefits/

News/ News/ R&D

Switch data back Chiesi/Protalix long-acting Fabry drug

Phil Taylor Chiesi, Fabrazyme, Fabry disease, Protalix, rare disease, Replagal, Sanofi Genzyme, Takeda 0 Comment

Chiesi and Protalix have built the case for their long-acting enzyme replacement therapy (ERT) for Fabry disease PRX-102,

Switch data back Chiesi/Protalix long-acting Fabry drug

https://pharmaphorum.com/news/switch-data-back-chiesi-protalix-long-acting-fabry-drug/

News/ News/ R&D

Moderna broadens R&D scope with Vertex, Chiesi alliances

Phil Taylor Chiesi, cystic fibrosis, Moderna, partnership, pulmonary arterial hypertension, Vertex Pharma 0 Comment

All eyes may be on Moderna’s COVID-19 vaccine at the moment, but the US biotech hasn’t been idle

Moderna broadens R&D scope with Vertex, Chiesi alliances

https://pharmaphorum.com/news/moderna-broadens-rd-scope-with-vertex-chiesi-alliances/

Market Access/ News/ News/ Top stories

Chiesi’s flagship Fabry drug heads for FDA verdict in early 2021

Phil Taylor Chiesi, Fabry disease, Protalix, rare disease 0 Comment

The FDA has started its review of Israeli biotech Protalix BioTherapeutics and partner Chiesi’s Fabry disease therapy pegunigalsidase

Chiesi’s flagship Fabry drug heads for FDA verdict in early 2021

https://pharmaphorum.com/news/chiesis-flagship-fabry-drug-heads-for-fda-verdict-in-early-2021/

R&D/ Views & Analysis/ Views and analysis

Chiesi ups its focus on rare diseases

Richard Staines Chiesi, Rare diseases 0 Comment

Italy’s Chiesi has created a new business unit aimed at increasing its presence in the market for rare

Chiesi ups its focus on rare diseases

https://pharmaphorum.com/r-d/views-analysis-r-d/chiesi-ups-its-focus-on-rare-diseases/

Trending

Chiesi

Login